Metraipolis › archive › dc_133baff42fff

Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a… — Europe PMC PMID:41578768

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41578768
DOI
10.5152/archrheumatol.2025.11098
License (as archived)
solo-consultazione
Archived
2026-11-08T01:48:36.579Z
SHA-256 of the archived text
5940751ff9105fa5551862466b74d600fa236edbfbfc6ea961054dbca7f9e1a0
Stable URL of this page
https://metraipolis.com/documento/dc_133baff42fff

How to cite

Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a… — Europe PMC PMID:41578768 — Europe PMC (en), https://europepmc.org/article/MED/41578768 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_133baff42fff (Metraipolis archive dc_133baff42fff, sha256 5940751ff9105fa5551862466b74d600fa236edbfbfc6ea961054dbca7f9e1a0)
BibTeX
@misc{dc133baff42fff,
  title = {Real-World Effectiveness and Safety of Upadacitinib in Tumor Necrosis FactorInhibitor Refractory Axial Spondyloarthritis: 52-Week Outcomes from a… — Europe PMC PMID:41578768},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41578768},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_133baff42fff; sha256 5940751ff9105fa5551862466b74d600fa236edbfbfc6ea961054dbca7f9e1a0},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41578768. Agents can read the archived copy with the MCP tool read_document.